Evaxion A/S (EVAX) Expected to Announce Quarterly Earnings on Thursday
by Scott Moore · The Cerbat GemEvaxion A/S (NASDAQ:EVAX – Get Free Report) will likely be announcing its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect the company to announce earnings of ($0.01) per share and revenue of $9.20 million for the quarter. Investors may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Thursday, May 7, 2026 at 8:30 AM ET.
Evaxion A/S Price Performance
Shares of NASDAQ EVAX opened at $4.57 on Tuesday. Evaxion A/S has a fifty-two week low of $1.42 and a fifty-two week high of $12.15. The business has a 50 day moving average price of $3.82 and a two-hundred day moving average price of $4.66. The company has a quick ratio of 5.85, a current ratio of 5.85 and a debt-to-equity ratio of 0.41. The firm has a market cap of $38.11 million, a PE ratio of -3.46 and a beta of 0.26.
Wall Street Analyst Weigh In
A number of equities research analysts have weighed in on EVAX shares. Lake Street Capital lowered their price objective on Evaxion A/S from $11.00 to $9.00 and set a “buy” rating for the company in a research note on Monday, March 9th. HC Wainwright restated a “buy” rating and set a $16.00 price objective on shares of Evaxion A/S in a research note on Friday, April 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Evaxion A/S in a research report on Friday, January 9th. Wall Street Zen lowered Evaxion A/S from a “buy” rating to a “hold” rating in a research report on Sunday, March 22nd. Finally, JonesTrading started coverage on Evaxion A/S in a research report on Tuesday, March 10th. They issued a “buy” rating and a $10.00 target price for the company. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Evaxion A/S presently has a consensus rating of “Moderate Buy” and an average price target of $11.00.
Get Our Latest Stock Analysis on EVAX
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Evaxion A/S stock. Northwestern Mutual Wealth Management Co. bought a new position in Evaxion A/S – Sponsored ADR (NASDAQ:EVAX – Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 8,000 shares of the company’s stock, valued at approximately $38,000. Northwestern Mutual Wealth Management Co. owned approximately 0.10% of Evaxion A/S at the end of the most recent quarter. Hedge funds and other institutional investors own 11.04% of the company’s stock.
About Evaxion A/S
Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.
At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.